TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Unity Biotechnology ( (UNBX) ) has shared an announcement.
On September 18, 2025, Unity Biotechnology held a special meeting of stockholders where the approval of the company’s liquidation and dissolution was voted on. The stockholders approved both the Dissolution Proposal and the Adjournment Proposal, granting the Board of Directors the authority to proceed with the dissolution at their discretion.
The most recent analyst rating on (UNBX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Unity Biotechnology stock, see the UNBX Stock Forecast page.
Spark’s Take on UNBX Stock
According to Spark, TipRanks’ AI Analyst, UNBX is a Underperform.
Unity Biotechnology’s overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.
To see Spark’s full report on UNBX stock, click here.
More about Unity Biotechnology
Unity Biotechnology, Inc. operates in the biotechnology industry, focusing on the development of therapeutics to slow, halt, or reverse diseases of aging.
Average Trading Volume: 581,294
Technical Sentiment Signal: Sell
Current Market Cap: $998.3K
See more data about UNBX stock on TipRanks’ Stock Analysis page.